Minkyeong P. Son
YOU?
Author Swipe
View article: Supplementary Figure Legends 1-7 from Carfilzomib Interacts Synergistically with Histone Deacetylase Inhibitors in Mantle Cell Lymphoma Cells <i>In Vitro</i> and <i>In Vivo</i>
Supplementary Figure Legends 1-7 from Carfilzomib Interacts Synergistically with Histone Deacetylase Inhibitors in Mantle Cell Lymphoma Cells <i>In Vitro</i> and <i>In Vivo</i> Open
PDF file - 117K
View article: Supplementary Figures 1-6 from Obatoclax Interacts Synergistically with the Irreversible Proteasome Inhibitor Carfilzomib in GC- and ABC-DLBCL Cells <i>In Vitro</i> and <i>In Vivo</i>
Supplementary Figures 1-6 from Obatoclax Interacts Synergistically with the Irreversible Proteasome Inhibitor Carfilzomib in GC- and ABC-DLBCL Cells <i>In Vitro</i> and <i>In Vivo</i> Open
PDF file - 402K, SFigure 1: Chemical structures of carfilzomib and obatoclax; SFigure 2: Co-treatment with carfilzomib and obatoclax synergistically induces cell death in SUDHL4 cells by Median Dose Effect analysis; SFigure 3: Combined tre…
View article: Data from Obatoclax Interacts Synergistically with the Irreversible Proteasome Inhibitor Carfilzomib in GC- and ABC-DLBCL Cells <i>In Vitro</i> and <i>In Vivo</i>
Data from Obatoclax Interacts Synergistically with the Irreversible Proteasome Inhibitor Carfilzomib in GC- and ABC-DLBCL Cells <i>In Vitro</i> and <i>In Vivo</i> Open
Interactions between the irreversible proteasome inhibitor carfilzomib and the pan-BH3 mimetic obatoclax were examined in germinal center (GC)- and activated B-cell–diffuse large B-cell lymphoma (ABC-DLBCL) cells. Cotreatment with minimall…
View article: Supplementary Figures 1-7 from Carfilzomib Interacts Synergistically with Histone Deacetylase Inhibitors in Mantle Cell Lymphoma Cells <i>In Vitro</i> and <i>In Vivo</i>
Supplementary Figures 1-7 from Carfilzomib Interacts Synergistically with Histone Deacetylase Inhibitors in Mantle Cell Lymphoma Cells <i>In Vitro</i> and <i>In Vivo</i> Open
PDF file - 284K
View article: Data from Obatoclax Interacts Synergistically with the Irreversible Proteasome Inhibitor Carfilzomib in GC- and ABC-DLBCL Cells <i>In Vitro</i> and <i>In Vivo</i>
Data from Obatoclax Interacts Synergistically with the Irreversible Proteasome Inhibitor Carfilzomib in GC- and ABC-DLBCL Cells <i>In Vitro</i> and <i>In Vivo</i> Open
Interactions between the irreversible proteasome inhibitor carfilzomib and the pan-BH3 mimetic obatoclax were examined in germinal center (GC)- and activated B-cell–diffuse large B-cell lymphoma (ABC-DLBCL) cells. Cotreatment with minimall…
View article: Supplementary Figure Legends 1-6 from Obatoclax Interacts Synergistically with the Irreversible Proteasome Inhibitor Carfilzomib in GC- and ABC-DLBCL Cells <i>In Vitro</i> and <i>In Vivo</i>
Supplementary Figure Legends 1-6 from Obatoclax Interacts Synergistically with the Irreversible Proteasome Inhibitor Carfilzomib in GC- and ABC-DLBCL Cells <i>In Vitro</i> and <i>In Vivo</i> Open
PDF file - 30K
View article: Data from Carfilzomib Interacts Synergistically with Histone Deacetylase Inhibitors in Mantle Cell Lymphoma Cells <i>In Vitro</i> and <i>In Vivo</i>
Data from Carfilzomib Interacts Synergistically with Histone Deacetylase Inhibitors in Mantle Cell Lymphoma Cells <i>In Vitro</i> and <i>In Vivo</i> Open
Interactions between the proteasome inhibitor carfilzomib and the histone deacetylase (HDAC) inhibitors vorinostat and SNDX-275 were examined in mantle cell lymphoma (MCL) cells in vitro and in vivo. Coadministration of very low, marginall…
View article: Supplementary Figure Legends 1-7 from Carfilzomib Interacts Synergistically with Histone Deacetylase Inhibitors in Mantle Cell Lymphoma Cells <i>In Vitro</i> and <i>In Vivo</i>
Supplementary Figure Legends 1-7 from Carfilzomib Interacts Synergistically with Histone Deacetylase Inhibitors in Mantle Cell Lymphoma Cells <i>In Vitro</i> and <i>In Vivo</i> Open
PDF file - 117K
View article: Supplementary Methods from Obatoclax Interacts Synergistically with the Irreversible Proteasome Inhibitor Carfilzomib in GC- and ABC-DLBCL Cells <i>In Vitro</i> and <i>In Vivo</i>
Supplementary Methods from Obatoclax Interacts Synergistically with the Irreversible Proteasome Inhibitor Carfilzomib in GC- and ABC-DLBCL Cells <i>In Vitro</i> and <i>In Vivo</i> Open
PDF file - 95K
View article: Supplementary Methods from Obatoclax Interacts Synergistically with the Irreversible Proteasome Inhibitor Carfilzomib in GC- and ABC-DLBCL Cells <i>In Vitro</i> and <i>In Vivo</i>
Supplementary Methods from Obatoclax Interacts Synergistically with the Irreversible Proteasome Inhibitor Carfilzomib in GC- and ABC-DLBCL Cells <i>In Vitro</i> and <i>In Vivo</i> Open
PDF file - 95K
View article: Data from Carfilzomib Interacts Synergistically with Histone Deacetylase Inhibitors in Mantle Cell Lymphoma Cells <i>In Vitro</i> and <i>In Vivo</i>
Data from Carfilzomib Interacts Synergistically with Histone Deacetylase Inhibitors in Mantle Cell Lymphoma Cells <i>In Vitro</i> and <i>In Vivo</i> Open
Interactions between the proteasome inhibitor carfilzomib and the histone deacetylase (HDAC) inhibitors vorinostat and SNDX-275 were examined in mantle cell lymphoma (MCL) cells in vitro and in vivo. Coadministration of very low, marginall…
View article: Supplementary Figures 1-6 from Obatoclax Interacts Synergistically with the Irreversible Proteasome Inhibitor Carfilzomib in GC- and ABC-DLBCL Cells <i>In Vitro</i> and <i>In Vivo</i>
Supplementary Figures 1-6 from Obatoclax Interacts Synergistically with the Irreversible Proteasome Inhibitor Carfilzomib in GC- and ABC-DLBCL Cells <i>In Vitro</i> and <i>In Vivo</i> Open
PDF file - 402K, SFigure 1: Chemical structures of carfilzomib and obatoclax; SFigure 2: Co-treatment with carfilzomib and obatoclax synergistically induces cell death in SUDHL4 cells by Median Dose Effect analysis; SFigure 3: Combined tre…
View article: Supplementary Figures 1-7 from Carfilzomib Interacts Synergistically with Histone Deacetylase Inhibitors in Mantle Cell Lymphoma Cells <i>In Vitro</i> and <i>In Vivo</i>
Supplementary Figures 1-7 from Carfilzomib Interacts Synergistically with Histone Deacetylase Inhibitors in Mantle Cell Lymphoma Cells <i>In Vitro</i> and <i>In Vivo</i> Open
PDF file - 284K
View article: Supplementary Figure Legends 1-6 from Obatoclax Interacts Synergistically with the Irreversible Proteasome Inhibitor Carfilzomib in GC- and ABC-DLBCL Cells <i>In Vitro</i> and <i>In Vivo</i>
Supplementary Figure Legends 1-6 from Obatoclax Interacts Synergistically with the Irreversible Proteasome Inhibitor Carfilzomib in GC- and ABC-DLBCL Cells <i>In Vitro</i> and <i>In Vivo</i> Open
PDF file - 30K
View article: Retraction: Carfilzomib Interacts Synergistically with Histone Deacetylase Inhibitors in Mantle Cell Lymphoma Cells <i>In Vitro</i> and <i>In Vivo</i>
Retraction: Carfilzomib Interacts Synergistically with Histone Deacetylase Inhibitors in Mantle Cell Lymphoma Cells <i>In Vitro</i> and <i>In Vivo</i> Open
This article (1) has been retracted at the request of the editors. The AACR Publications Department was notified that the U.S. Department of Health and Human Services' Office of Research Integrity (ORI) determined that G. Dasmahapatra, the…
View article: DNA Damage Reduces the Quality, but Not the Quantity of Human Papillomavirus 16 E1 and E2 DNA Replication
DNA Damage Reduces the Quality, but Not the Quantity of Human Papillomavirus 16 E1 and E2 DNA Replication Open
Human papillomaviruses (HPVs) are causative agents in almost all cervical carcinomas. HPVs are also causative agents in head and neck cancer, the cases of which are increasing rapidly. Viral replication activates the DNA damage response (D…